BioAffinity Technologies Revenue and Competitors
Estimated Revenue & Valuation
- BioAffinity Technologies's estimated annual revenue is currently $4.5M per year.
- BioAffinity Technologies's estimated revenue per employee is $155,000
Employee Data
- BioAffinity Technologies has 29 Employees.
- BioAffinity Technologies grew their employee count by 38% last year.
BioAffinity Technologies's People
Name | Title | Email/Phone |
---|
BioAffinity Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is BioAffinity Technologies?
N/A
Total Funding
29
Number of Employees
$4.5M
Revenue (est)
38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BioAffinity Technologies News
2022-04-20 - bioAffinity Technologies Files For U.S. IPO
bioAffinity Technologies has filed to raise capital via a U.S. IPO. The firm is developing a lung cancer detection test for use in the U.S....
2022-04-17 - Lung cancer diagnostics developer bioAffinity Technologies ...
bioAffinity Technologies, which has developed a noninvasive test for early detection of lung cancer, filed on Monday with the SEC to raise...
2022-04-17 - Lung cancer test developer BioAffinity files for $19M IPO
BioAffinity Technologies (BIAF), which is developing a test to better detect lung cancer in its earliest stages, has filed for a $19M...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.6M | 29 | 26% | N/A |
#2 | $5M | 29 | 12% | N/A |
#3 | $7.5M | 29 | 4% | N/A |
#4 | $3.6M | 29 | -22% | $78.5M |
#5 | $5M | 29 | 0% | N/A |